Allogene Therapeutics Inc. (NASDAQ:ALLO) currently has a daily average trading volume of 2.07M but it saw 1947004 shares traded on Wednesday. With a market cap of 829.83M USD, stock’s current market price of $5.69 came falling about -5.95 while comparing to the previous closing price of $6.05. In past 52 weeks, the stock remained buoying in the range of price level as high as $17.49 and as low as $4.42. In the recent trading on the day, stock has struck highest price mark of $6.12 while lowest mark touched by it was $5.52.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Taking a look at 20-day trading activity of Allogene Therapeutics Inc. (ALLO) gives us an average price of $6.03, while its current price level is -67.47% below from 52-week high level whereas it is 28.73% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $5.46 while that of 200 days or SMA-200 reads an average of $8.59. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.31% during that period while stretching the period over a month that increases to 7.36%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 46.18 which implies that the stock is in neutral territory.
Allogene Therapeutics Inc. (ALLO)’s stock is currently under the radar of 19 analysts who are in consensus at a 12-month price target range of between $6.00 and $35.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $6.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $35.00. Average price target assigned by them is $16.91 which highlights an upside potential of 66.35% for the stock over that period. And to attain the median price target of $15.00 assigned by those analysts, stock has to add about 62.07% of value to its current levels.
Data by FactSet Research shows that 19 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 1 are advising it as an Overweight. 14 analysts suggested the investors to Buy the stock while 3 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Overweight for the stock and that issued by Wall Street to investors is Strong Buy.
Over the week, ALLO’s stock price is moving -7.03% down while it is 1.61% when we observe its performance for the past one month. Year-to-date it is -9.54% down and over the past year, the stock is showing a downside performance of -23.73%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$0.68 beaten by the consensus estimate of -$0.62 for the same. The company is expected to be releasing its next quarterly report in 08/09/2023, for which analysts forecasted an EPS of -$0.59 while estimate for next year EPS is -$2.36. For ALLO, analysts are forecasting an EPS-growth rate of -1.70% for current year and estimate for EPS growth in next year is 1.30%. In next quarter, company is expected to be making quarterly sales of $10k as analysts are expecting the sales for current fiscal year at $70k and seeing the company making $30k in sales next year. Moreover, analysts are in estimates of $20k for current-quarter revenue.
Currently, Allogene Therapeutics Inc.’s total number of outstanding shares is 144.56M with 29.16% of that held by the insiders while 78.32% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -50.20%. Stock’s beta reads 0.75. Stock has a price to book (P/B) ratio of 1.39 while price to sale or P/S ratio amounts to 4149.15. Its return on asset (ROA) is -41.40% on average.
A filing at the U.S. Securities and Exchange Commission revealed that SPDR S&P Biotech ETF came shrinking its share ownership by 1.78% in the Allogene Therapeutics Inc. (ALLO) increasing its stake to 4.04% with control over 0.1 million shares in the company. In the most recent quarter, Vanguard Capital Opportunity Fund came rising its stake by 1.11% in the company and now holds 2.88 million or 1.99% of the company’s stake having worth of about 15.62 million.
Leave a Reply